Syngene International: Biocon sells 5.4% stake in arm Syngene International - The Economic Times
Fortune India: Business News, Strategy, Finance and Corporate Insight
Biocon subsidiary acquires Viatris pharma for $3 billion | Mint
Exclusive | Biocon, Mylan Biosimilar Deal in Last Leg; Serum Institute to Buy Additional Stake of $500 Million in Biocon Biologics: Sources
Biocon Academy - Biocon
Biocon - Crunchbase Company Profile & Funding
Biocon announces merger of its arm with Serum Institute subsidiary - BusinessToday
Biocon - Wikipedia
Manufacturing Locations - Biocon
Biocon logo in transparent PNG format
Research Centre - Biocon
Biocon Q4 results show Consolidated revenue up by 21% - The Statesman
Biocon Biologics appoints Susheel Umesh as Chief Commercial Officer for emerging markets | Deccan Herald
Biocon biosimilar plant criticized again by the FDA | Fierce Pharma
Meet Biocon Biologics: A 2021 Facility of the Year Honorable Mention Award Winner | Pharmaceutical Engineering
Biocon Biologics, Serum Institute Life Sciences enter strategic alliance
Covid has created an 'ecosystem' of innovation in India, says Biocon chief Kiran Mazumdar-Shaw | Mint
Biocon sells 5.4% stake in its research arm Syngene International - Hindustan Times
Cash-and-stock deal: Biocon Biologics acquires Viatris for $3.33 billion | The Financial Express
Biocon - 72 new faces joined us in February. Many... | Facebook
Biocon Biologics enters licensing agreement with Yoshindo of Japan - The Hindu BusinessLine
Meet Biocon Biologics: A 2021 Facility of the Year Honorable Mention Award Winner | Pharmaceutical Engineering
Joint drugs controller nabbed taking bribe to clear Biocon Biologics's diabetes injection | Mint
